PSA-PU

Public Storage

NYSE· CIK 0001393311

Preferred stock of Public Storage · PSA stock page →

$21.49 −0.51 (−2.32%)

Oct 27 4:00 PM ET · prev $22.00

Market cap

$57.9B

Large cap

Since first trade

−20.6%

from $27.05 · Jul 23

30 days

−0.8%

from $21.67

Range since listing

$21.32–32.00

−33% from high · low Oct 23

Avg volume 20D

3.8K

Sep 30 spike 17.1K

Price

Daily candles with volume.

Signal stack

Where each data set points today.

TrendDOWNTREND

5% below its 50-day average. New closing low $21.32 on Oct 23.

Catalysts

Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.

Recent

Oct 16, 2026

Drug approval

EMA: Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion

Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion

Oct 15, 2026

Drug approval

EMA: Human medicines European public assessment report (EPAR): Rasonque, Daraxonrasib, Status: Opinion

Human medicines European public assessment report (EPAR): Rasonque, Daraxonrasib, Status: Opinion

Jul 24, 2026

Drug approval

EMA: Human medicines European public assessment report (EPAR): Lyrokaul, lerodalcibep, Status: Opinion

Human medicines European public assessment report (EPAR): Lyrokaul, lerodalcibep, Status: Opinion

Jul 24, 2026

Drug approval

EMA: Human medicines European public assessment report (EPAR): Evlarco, obicetrapib,ezetimibe, Status: Opinion

Human medicines European public assessment report (EPAR): Evlarco, obicetrapib,ezetimibe, Status: Opinion

Jul 24, 2026

Drug approval

EMA: Human medicines European public assessment report (EPAR): Meplyffa, arimoclomol, Status: Opinion

Human medicines European public assessment report (EPAR): Meplyffa, arimoclomol, Status: Opinion

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

Period	EPS est.	Range	30D rev.	Revenue
Current Q	🔒 Fresh data, subscribers only
Next Q	🔒 Fresh data, subscribers only
Current FY	🔒 Fresh data, subscribers only
Next FY	🔒 Fresh data, subscribers only

Recent activity

The latest filings, insider trades, analyst actions, press and options flow — newest first.

Oct 16, 2026 Drug approval

EMA: Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion

Human medicines European public assessment report (EPAR): Yuviwel, Navepegritide, Status: Opinion